Overview
Corcept Therapeutics (NASDAQ: CORT) is a commercial-stage biotech focused on drugs that modulate cortisol. Its only marketed drug, Korlym (mifepristone), was approved in 2012 for endogenous Cushing’s syndrome (smartinvestorsdaily.com). This single product drove Corcept’s 2024 revenue to $675.0 million (up 40% YoY) (ir.corcept.com) (ir.corcept.com) and 2025 revenue to $761.4 million (up 13% YoY) (www.biospace.com) (www.biospace.com). However, in late 2025 Corcept was rocked by a major regulatory setback: the FDA issued a Complete Response Letter (CRL) rejecting Corcept’s New Drug Application for relacorilant (its lead cortisol modulator) as a treatment for Cushing’s-related hypertension (smartinvestorsdaily.com) (www.fiercebiotech.com). The FDA had explicitly warned Corcept “on several occasions” during pre-NDA meetings that the clinical data were inadequate and to “expect significant review issues” if it filed (www.fiercebiotech.com). Corcept’s management nevertheless expressed “high confidence” publicly – claiming relacorilant was supported by “powerful evidence” and “approaching approval” – only to profess “surprise and disappointment” when the CRL arrived on Dec. 30, 2025 (www.prnewswire.com) (www.fiercebiotech.com). The rejection highlighted evidence gaps (key trials failed primary endpoints or had overly small, post-hoc subsets) that made a favorable benefit-risk assessment impossible without additional studies (www.fiercebiotech.com) (www.fiercebiotech.com). The news triggered a frenzied sell-off – CORT’s stock plunged about 50% from ~$70 to the mid-$30s (www.hbsslaw.com) (www.fiercebiotech.com), erasing over $3.6 billion in market value in one day (www.hbsslaw.com).
In the wake of this plunge, Hagens Berman (a shareholder rights law firm) announced a class-action lawsuit alleging Corcept misled investors about relacorilant’s prospects (www.prnewswire.com). The complaint claims Corcept concealed repeated FDA warnings and overstated relacorilant’s efficacy, creating a false narrative of an “approaching” approval (www.prnewswire.com) (www.globenewswire.com). When the truth emerged via the CRL, shareholders suffered heavy losses. The suit covers investors who bought CORT stock Oct 31, 2024 through Dec 30, 2025, and seeks to recover damages for the ~50% decline (www.prnewswire.com) (www.hbsslaw.com). Investors with significant losses are encouraged to contact Hagens Berman to discuss their rights before the lead plaintiff deadline of April 21, 2026 (www.globenewswire.com) (www.globenewswire.com). This legal action underscores the gravity of Corcept’s setbacks and sets the stage for closer scrutiny of the company’s disclosures and governance. Below, we dive into Corcept’s fundamentals – from its shareholder returns and balance sheet to valuation, risks, and red flags – to provide a full picture of the situation.
Dividend Policy & Shareholder Returns
Corcept does not pay a dividend, opting instead to return capital via share repurchases (current dividend yield = 0% (smartinvestorsdaily.com)). The company has never declared a cash dividend, which is typical for growth-focused biotechs that reinvest profits. Instead, in January 2024 Corcept’s board authorized a $200 million stock buyback program (ir.corcept.com). Under this program the company repurchased $38.0 million of stock during 2024 (smartinvestorsdaily.com) and then accelerated buybacks in 2025, buying back $115.4 million worth of shares in just Q2 2025 (smartinvestorsdaily.com). These repurchases have modestly reduced the share count and signal management’s confidence in the business (smartinvestorsdaily.com) (smartinvestorsdaily.com). Notably, Corcept had $603.2 million cash on hand at 2024’s end (ir.corcept.com), and despite ~$153 million spent on buybacks in 2024–25, it still held $532.4 million in cash and investments as of Dec 31, 2025 (www.biospace.com). This sizable cash war chest has funded shareholder returns without sacrificing growth initiatives. While investors receive no direct dividend income, Corcept’s active buybacks have been its way of rewarding shareholders and instilling market confidence.
Balance Sheet & Leverage
Corcept maintains a conservative balance sheet, with almost no debt and substantial liquidity. In fact, the company’s long-term debt is $0 – it has carried essentially no interest-bearing debt in recent years (smartinvestorsdaily.com) (smartinvestorsdaily.com). As a result, Corcept’s debt-to-equity ratio is ~0% and there are no large debt maturities or interest obligations looming (smartinvestorsdaily.com) (smartinvestorsdaily.com). Instead of debt, Corcept relies on internally generated cash and its $500M+ cash reserve for funding. By year-end 2025, cash and investments totaled $532.4 million (www.biospace.com), comfortably exceeding total liabilities. The company is actually a net creditor – likely earning interest income on its cash (given rising interest rates) rather than paying interest expense. This debt-free position gives Corcept high financial flexibility. It faces none of the refinancing or interest-coverage risks that leveraged biotechs might. In fact, with no debt, Corcept’s interest coverage is a non-issue – operating profits easily cover the minimal lease or working-capital obligations on its books. The strong balance sheet has enabled Corcept to weather setbacks (like the CRL) without liquidity strain, and to continue strategic investments (R&D, buybacks) even during turbulence. In short, leverage is not a concern here – Corcept’s capital structure is equity-rich and built to support long-term growth.
Valuation & Performance
Even after the recent sell-off, Corcept remains profitable and is guiding for growth, though its valuation has reset to reflect higher risks. At a stock price in the mid-$30s, CORT trades around 28× trailing earnings (using 2024 EPS of $1.23) (smartinvestorsdaily.com) (smartinvestorsdaily.com). This represents a far lower P/E than before the CRL – prior to the crash, the stock was priced for near-certain relacorilant approval (over 50× earnings). Now the valuation is more modest, pricing Corcept more like a steady single-product biotech than a high-flying growth story. On a revenue basis, CORT is valued at roughly 5× forward sales (enterprise value ~5 times 2025’s ~$825M revenue forecast) (smartinvestorsdaily.com). For context, Corcept’s 2025 sales came in at $761.4M (www.biospace.com) (www.biospace.com) with net income of $99.7M (EPS $0.82) (www.biospace.com) (www.biospace.com). Profit margins compressed in 2025 (net margin ~13% vs ~21% in 2024) as R&D spending jumped to support multiple trials (smartinvestorsdaily.com) (smartinvestorsdaily.com) and one-time supply bottlenecks curbed revenue. Despite the relacorilant setback, management is guiding 2026 revenue to $900–$1,000M (www.biospace.com) (18–31% growth), expecting Cushing’s drug demand to rebound now that distribution issues are resolved (www.biospace.com) (www.biospace.com). If achieved, that growth could improve forward earnings and make the current P/E look even more reasonable.
Tap to reveal how to get exposure pre-IPO
Analyst opinions are mixed after the FDA rejection. Some see the sell-off as overdone: for example, Morgan Stanley kept an Overweight rating and only cut its price target from $140 to $99, citing Korlym’s continued growth and minimal near-term generic impact (smartinvestorsdaily.com). H.C. Wainwright likewise reiterated a Buy (trimmed target $145→$90), noting the CRL likely delays relacorilant by ~3 years but doesn’t destroy its long-term value (smartinvestorsdaily.com). On the bearish side, at least one firm (Truist) slashed its target dramatically (e.g. $135 down to $50) yet even that is above the current price (smartinvestorsdaily.com). In sum, the market is now pricing CORT as a one-trick pony with an uncertain pipeline, whereas before it was valued for blockbuster expectations. If Korlym’s cash flows prove durable and the company can deliver new products, there may be upside from these levels – but the valuation appropriately discounts the elevated risks (detailed below).
Risks
Regulatory & Pipeline Risk: The FDA’s CRL for relacorilant in Cushing’s syndrome is a major blow. To eventually win approval, Corcept will likely need at least one new Phase 3 trial to gather “additional evidence of effectiveness,” which could delay relacorilant’s Cushing’s launch by several years (possibly to 2028–2029) (smartinvestorsdaily.com) (smartinvestorsdaily.com). There is no guarantee a new trial will succeed – the prior studies had limitations (one Phase 3 failed its primary endpoint outright (www.fiercebiotech.com)). If relacorilant never gains approval for Cushing’s, Corcept loses its most important growth driver. The company is meeting with the FDA to find a path forward (smartinvestorsdaily.com), but this indication’s outlook is significantly dimmed (smartinvestorsdaily.com). Beyond Cushing’s, Corcept’s pipeline includes relacorilant in oncology and earlier-stage candidates (e.g. dazucorilant for ALS, a program in NASH) (ir.corcept.com). These carry typical clinical trial risk – efficacy is unproven and development is costly. Failure of key pipeline programs (or inability to finance them if cash flows decline) would hurt Corcept’s future prospects.
Concentration & Competition: Corcept currently relies almost entirely on Korlym for revenue (smartinvestorsdaily.com) (smartinvestorsdaily.com). This Cushing’s franchise faces competition and will eventually face generics. Two newer Cushing’s therapies are already on the market – Recordati’s Isturisa® (osilodrostat) and Xeris’s Recorlev® (levoketoconazole) – approved in 2020–2021 (smartinvestorsdaily.com). Another option, Novartis’s Signifor® (pasireotide), also targets Cushing’s (smartinvestorsdaily.com). While Korlym (a cortisol receptor blocker) remains unique in mechanism and has been growing with increased disease awareness (smartinvestorsdaily.com) (smartinvestorsdaily.com), doctors now have alternatives. Accelerating adoption of these competing drugs could erode Korlym’s market share over time (smartinvestorsdaily.com). Moreover, all of Corcept’s revenue comes from one niche (hypercortisolism) (smartinvestorsdaily.com) – any setback with Korlym (safety issues, new competitors, etc.) would substantially impact financial results. This lack of diversification makes the company especially vulnerable to external shocks in the Cushing’s treatment landscape.
Intellectual Property & Generic Threat: Perhaps the biggest risk is generic competition for Korlym. Corcept has been embroiled in patent litigation, and generics are closer to market than many realize. Teva launched a generic version of Korlym “at risk” in January 2024 (ir.corcept.com) (ir.corcept.com) after a court ruled that Teva’s product did not infringe certain Corcept patents (ir.corcept.com) (ir.corcept.com). Corcept is appealing that December 2023 decision, but there is no assurance the appeal will succeed (ir.corcept.com) (ir.corcept.com). If the appeal fails, Teva (and others) will have free rein. In fact, Corcept already settled litigation with generic makers Sun Pharma and Hikma – allowing them to launch their own mifepristone generics by 2034 or sooner if another generic (like Teva’s) is on the market (ir.corcept.com). This means Teva’s early entry could open the floodgates to multiple generics. The company warned that if Teva’s generic remains on sale, Sun and Hikma could also come to market, causing Korlym sales to decline “rapidly and significantly.” (ir.corcept.com) (ir.corcept.com) An influx of low-priced generics would likely slash Corcept’s revenue and margins, given Korlym represented ~100% of sales (smartinvestorsdaily.com) (smartinvestorsdaily.com). Even if Corcept ultimately wins its appeal (forcing Teva to withdraw and pay damages), significant damage could be done in the interim. Investors should appreciate that Korlym’s exclusivity is precarious – an adverse legal outcome could transform Corcept’s financial profile almost overnight. This patent risk is a key overhang on the stock.
Execution & Operational Risks: Corcept’s recent stumble with its specialty pharmacy vendor highlights execution risk. In 2025, demand for Korlym exceeded the capacity of Corcept’s sole specialty pharmacy, causing fulfillment shortfalls (ir.corcept.com) (ir.corcept.com). This was cited as a reason for trimming 2025 revenue guidance mid-year (smartinvestorsdaily.com). The company has since added a second pharmacy and completed a vendor transition by Q1 2026 (www.biospace.com) (www.biospace.com). While that should resolve the bottleneck, any operational disruptions in distribution can directly hit sales (as seen in 2025). Additionally, Corcept’s expenses – especially R&D – have been rising as it advances multiple trials (smartinvestorsdaily.com) (smartinvestorsdaily.com). If revenue growth stalls or contracts (due to generics or other issues), profitability could quickly deteriorate, and Corcept might need to cut or prioritize R&D projects. Managing growth (or contraction) and cost discipline will be crucial going forward. Lastly, typical biotech risks around manufacturing, regulatory compliance, and market adoption apply – e.g. ensuring adequate drug supply, navigating FDA requirements for any new indications, and persuading physicians to use its therapies in face of competition.
Red Flags & Legal Issues
Corcept’s recent troubles raise red flags about management transparency and practices. The class action led by Hagens Berman alleges that Corcept knowingly ignored FDA warnings about relacorilant and failed to disclose those concerns to investors (www.prnewswire.com) (www.fiercebiotech.com). If true, this indicates a serious lapse in corporate governance – essentially misleading investors on a material issue (the viability of its lead drug). The gap between the FDA’s private cautions and Corcept’s public optimism (“high confidence,” “approaching approval”) (www.prnewswire.com) (www.globenewswire.com) suggests management may have put an overly positive spin on relacorilant’s data. Such actions have now triggered the pending securities fraud lawsuit, which will keep Corcept under a microscope. Shareholders should monitor this case, as it could unearth internal communications revealing what executives knew versus what they said. Even if Corcept ultimately settles (as is common), the episode has dented management’s credibility and could lead to stricter oversight or changes in leadership.
Importantly, this is not the first time Corcept’s conduct has come under legal scrutiny. In April 2023, Corcept paid $14 million to settle a prior securities litigation that alleged improper off-label marketing of Korlym (www.law360.com) (www.law360.com). Investors had accused the company of inflating sales by promoting Korlym for unapproved uses, and a deal was struck to end the case (www.law360.com). Around the same time, reports emerged of a DOJ investigation into Corcept’s Korlym marketing practices and relationships with doctors (thecapitolforum.com). The company disclosed receiving a DOJ subpoena for records in late 2021, suggesting potential scrutiny of off-label promotion (thecapitolforum.com). These historical issues point to a pattern of aggressive sales tactics that pushed ethical boundaries. They raise concerns that Corcept’s culture incentivized risky behavior to drive growth – whether via off-label sales or overconfident statements to investors. While Corcept has not admitted wrongdoing, the fact that it settled the off-label case and is now facing another class action is a red flag for shareholders. It implies that internal controls or management judgments have been questionable. Going forward, Corcept may operate under heightened regulatory and legal oversight, and investors will demand greater transparency. In summary, past and present legal troubles cast doubt on management’s forthrightness – a risk factor that goes beyond numbers and into trust.
Open Questions & Outlook
Looking ahead, several critical questions remain for Corcept’s investors:
– Can relacorilant be salvaged for Cushing’s? Corcept insists the story isn’t over – they plan to work with FDA on a path forward and were “more confident than ever” in relacorilant’s potential prior to the CRL (www.hbsslaw.com) (www.hbsslaw.com). However, any new trial will take years and success is uncertain. How willing is Corcept to pour more R&D dollars into a do-over study? And if new data eventually come, will the regulatory bar be higher given the initial shortcomings? Investors must consider relacorilant’s delayed timeline and the opportunity cost of chasing an approval that might not arrive. This will be a key strategic decision for the company in 2026.
– What will happen on July 11, 2026? That is the FDA’s decision deadline (PDUFA date) for relacorilant’s separate indication in platinum-resistant ovarian cancer (smartinvestorsdaily.com). Notably, relacorilant succeeded in a Phase 3 ovarian cancer trial (the ROSELLA study met its primary endpoint, improving progression-free survival) (www.fiercebiotech.com). The Cushing’s CRL does not directly affect this oncology filing (smartinvestorsdaily.com). If the FDA approves relacorilant for ovarian cancer by mid-2026, Corcept could launch a second revenue stream in oncology. In fact, the company announced a phase 3 win in ovarian cancer in Jan 2026, which sent the stock up sharply (an 85% jump that day) (www.fiercebiotech.com). An approval could validate Corcept’s cortisol modulation approach in a new domain and partly redeem relacorilant’s value. Open questions include: How large is the ovarian cancer opportunity (niche use or significant market)? Will Corcept commercialize alone or seek a partner in oncology? And can positive news here rebuild investor confidence even as the Cushing’s indication remains in limbo?
– Will Korlym’s growth run off track? Despite competition and a near-miss with supply issues, Corcept has been bullish that its Cushing’s business will expand for years (www.biospace.com) (www.biospace.com). The “true prevalence” of hypercortisolism is higher than historically recognized, and better screening is driving more diagnoses (ir.corcept.com) (ir.corcept.com). Indeed, Corcept continues to report record numbers of patients starting Korlym and new prescribing physicians each quarter (ir.corcept.com). February 2026 was on track to be a record month for new patient starts after the pharmacy transition (www.biospace.com) (www.biospace.com). This raises a question: Can organic Korlym growth offset potential future headwinds? In the short term, if generics are kept at bay through 2026 (e.g. pending appeal), Corcept could hit its $900M+ revenue guidance on Korlym momentum alone (www.biospace.com). But if Teva’s generic or others gain traction, even brisk demand might not translate to sales – patients could be siphoned to cheaper alternatives. Investors will be watching how Korlym performs in 2026: do sales re-accelerate now that distribution is fixed, or do we see an impact from the generic launch in 2024? Any subtle signs of market share erosion or pricing pressure will be pivotal. Korlym’s durability in the face of competition (both branded and generic) remains an open question critical to Corcept’s valuation.
– How will the patent and antitrust battles resolve? The legal overhang is complex. The appeal of the Teva patent ruling is one piece – if Corcept wins on appeal, it could potentially remove Teva’s generic (at least temporarily) and preserve exclusivity. A decision could come in 2026. Another piece: Teva’s separate antitrust lawsuit against Corcept (alleging anti-competitive conduct with its specialty pharmacy) (ir.corcept.com) (ir.corcept.com). Corcept is fighting those allegations, but if any evidence of anti-competitive practices is found, it could lead to penalties or mandated changes in distribution. Additionally, a group of plaintiffs filed a lawsuit in Feb 2025 echoing Teva’s antitrust claims (ir.corcept.com), indicating broader legal pressures. How these cases play out will influence Corcept’s operating environment – e.g. whether it can maintain a single-pharmacy distribution model (important for controlling Korlym access/pricing) or not. Investors should keep an eye on legal updates, as outcomes here will answer if Corcept can sustain its business model or if generics and legal constraints will fundamentally alter it.
– Corporate governance and leadership: With a second shareholder lawsuit (the Hagens Berman case) underway, one wonders if management or board changes could follow. CEO Joseph Belanoff, who co-founded Corcept, has led the company for decades and projected optimism even amid controversy (www.fiercebiotech.com) (www.biospace.com). If the class action uncovers serious misrepresentations, will there be pressure for new leadership or enhanced oversight? Corcept’s investor communications will also be in focus – the company may need to rebuild trust by providing clearer, more tempered guidance. An open question is whether Corcept will adjust its strategy or culture in response to these events (for example, being more conservative in pipeline promises or compliance practices). Any hints of changes in tone or personnel in 2026 could signal lessons learned – or, if absent, could be a warning sign of business-as-usual despite the red flags.
Finally, will investors stick around or join the legal fight? The class period losses are substantial; some shareholders may opt to participate in the class action to seek redress. Others may see the current stock price as an opportunity if they believe Korlym’s cash flows and the pipeline (ovarian cancer, etc.) can still create long-term value once the dust settles. In essence, Corcept’s story is at a crossroads: either a rebound – powered by resilient Cushing’s drug sales and a second act in oncology – or a decline if legal/regulatory hurdles prove too great. How the next few quarters unfold on both the business and legal fronts will be telling. Investors should closely watch FDA decisions, court rulings, and Corcept’s own moves. CORT remains a high-risk, high-reward situation, with unanswered questions that will determine whether this dramatic 50% plunge was a temporary setback or a harbinger of more challenges to come.
Sources: Corcept Therapeutics SEC filings and press releases; Hagens Berman class action announcement (www.prnewswire.com) (www.globenewswire.com); FierceBiotech and other financial media analyses (www.fiercebiotech.com) (smartinvestorsdaily.com); Zacks Equity Research (www.zacks.com) (www.zacks.com); Law360 legal news (www.law360.com). (All source links above)
For informational purposes only; not investment advice.
